Health Care·Biotechnology·$6.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.38 | N/A | +7.32% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.38 | N/A | +7.32% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a sense of cautious optimism regarding their clinical developments. However, they did not offer specific guidance for future quarters.
Management highlighted ongoing progress in their clinical trials.
They expressed confidence in their pipeline despite not providing specific guidance.
Centessa Pharmaceuticals reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the stock declined by 1.56% following the earnings report, likely due to the lack of revenue figures and forward guidance. The cautious tone from management may have contributed to investor uncertainty.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ALGONQUIN PWR & UTIL
May 10, 2024